Company Overview

GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA. 

This new approach is the result of 25 years of research on endogenous retroviruses, including 15 within Institut Mérieux and INSERM, before the creation of GeNeuro in 2006. This research has allowed us to discover and understand the action of a factor potentially causative of multiple sclerosis, the pathogenic MSRV protein, which is a member of the human endogenous retrovirus-W family (HERV-W). The presence of pathogenic HERV-W in the brains of patients may be an important cause of the inflammatory and neurodegenerative phenomena characterizing this disease.

GeNeuro has developed GNbAC1, a humanized monoclonal antibody, currently in Phase IIb clinical development in multiple sclerosis with the support of Servier, the context of a 362 M€ partnership signed in 2014. By neutralizing the pathogenic HERV-W protein rather than targeting the patient's immune system, GNbAC1 could prove to be both safe and effective, and potentially able to slow or even halt the progression of the disease in all its forms.

GeNeuro develops its platform against other autoimmune diseases, such as type 1 diabetes for which a 60-patient Phase lla with GNbAC1 was launched in April 2017, and chronic inflammatory demyelinating polyneuropathy for which a proof-of-concept trial is planned to be launched by end of 2017.

To capture the full therapeutic potential of its approach against pathogenic HERV proteins, GeNeuro is developing new therapeutics, currently at preclinical stage, against other pathologies such as inflammatory psychosis, as well as against amyotrophic lateral sclerosis for which GeNeuro has signed a research partnership with the NIH.

GeNeuro SA is a member of the Swiss Biotech Association, a member of the BioAlps community and has the CTI (Commission for Technology and Innovation) start-up label.
GeNeuro Innovation SAS is member of the French Lyon Biopole.

More about the pipeline
More about multiple sclerosis
More about schizophrenia